StreetInsider.com News Articles

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Wed, 21 Oct 2026 16:01:00 -0400

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences:

Wolfe Research Healthcare Conference 2026: Tuesday, November 10, 2026
- Company fireside chat starting at 8:00 a.m. ET

Stifel 2026 Healthcare Conference: Wednesday, November 11, 2026
- Company fireside chat starting at 1:20 p.m. ET

2026 Jefferies Global Healthcare Conference: Tuesday, November 17, 2026
- Company presentation starting at 12:30 p.m. GMT

The presentation and fireside chats will be webcast live and can be accessed by visiting the Investors section of

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Wed, 21 Oct 2026 16:01:00 -0400

Wolfe Research Healthcare Conference 2026: Tuesday, November 10, 2026
- Company fireside chat starting at 8:00 a.m. ET

Stifel 2026 Healthcare Conference: Wednesday, November 11, 2026
- Company fireside chat starting at 1:20 p.m. ET

2026 Jefferies Global Healthcare Conference: Tuesday, November 17, 2026
- Company presentation starting at 12:30 p.m. GMT

The presentation and fireside chats will be webcast live and can be accessed by visiting the Investors section of

Mirum Pharmaceuticals (MIRM) PT Raised to $145 at TD Cowen

Wed, 21 Oct 2026 08:12:18 -0400

TD Cowen analyst Joseph Thome raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $145.00 (from $140.00) while maintaining a Buy rating.

Form 4 Mirum Pharmaceuticals, For: Oct 16 Filed by: Howe Jolanda

Mon, 19 Oct 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20261019/27203960.html

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 15 Oct 2026 16:01:00 -0400

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on October 9, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 18,663 shares of common stock and 24,687 restricted stock units (“RSUs”) to 18 new employees under Mirum’s 2020 Inducement Plan. Additionally, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 40,000 shares of common stock and 25,000 RSUs under Mirum’s 2020 Inducement Plan to the company’s newly appointed Chief

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 15 Oct 2026 16:01:00 -0400

Mirum Pharmaceuticals (MIRM) PT Raised to $156 at Stifel on Clinical/Regulatory Wins

Thu, 15 Oct 2026 09:34:13 -0400

Stifel analyst James Condulis raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $156.00 (from $136.00) while maintaining a Buy rating.

The analyst commented, "We're increasing our TP following recent clinical/regulatory wins (FOP approval; HDV/EXPAND ph3 wins)--details in our full note. Taking a step back--we've gotten many questions re:MIRM's weakness. Besides the tape, part of the dynamic with MIRM is that the debates are largely commercial while there's naturally also a big focus on the PSC regulatory path which--even as the Street is generally optimistic-- creates uncertainty as its unclear if/when there will be an "alignment" catalyst before filing. Naturally

Mirum Pharmaceuticals (MIRM) PT Raised to $156 at Stifel on Clinical/Regulatory Wins

Thu, 15 Oct 2026 09:34:13 -0400

Stifel analyst James Condulis raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $156.00 (from $136.00) while maintaining a Buy rating.

Form 4 Mirum Pharmaceuticals, For: Oct 09 Filed by: Myers Robert Paul

Wed, 14 Oct 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20261014/27187176.html

Form 8-K Mirum Pharmaceuticals, For: Oct 12

Tue, 13 Oct 2026 08:09:00 -0400

si-local-file:///var/storage/secattach/20261013/27177603.html

Mirum Pharmaceuticals (MIRM) PT Raised to $152 at Morgan Stanley

Tue, 13 Oct 2026 05:18:19 -0400

Morgan Stanley analyst Michael E Ulz raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $152.00 (from $137.00) while maintaining a Overweight rating.

The analyst comments "Raising price target to $152. Based on these data, we increase our price target to $152 from $137, driven by increasing our probability of success for the EXPAND study patient populations to 100% from 60%. We reiterate our OW rating as we expect momentum to continue ahead of multiple catalysts expected in the coming quarters."

Mirum Pharmaceuticals (MIRM) PT Raised to $152 at Morgan Stanley

Tue, 13 Oct 2026 05:18:19 -0400

Morgan Stanley analyst Michael E Ulz raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $152.00 (from $137.00) while maintaining a Overweight rating.

Mirum Pharmaceuticals (MIRM) PT Raised to $184 at Citi

Mon, 12 Oct 2026 13:57:55 -0400

Citi analyst Yigal Nochomovitz raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $184.00 (from $160.00) while maintaining a Buy rating.

Raymond James on Mirum Pharmaceuticals (MIRM): 'we think its ~$1B+ estimate for the Livmarli opportunity is continuing to look more and more conservative'

Mon, 12 Oct 2026 10:43:23 -0400

Raymond James analyst Steven Seedhouse reiterated a Strong Buy rating and $183.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).

The analyst comments "In the EXPAND study, designed to evaluate Mirum’s lead IBAT inhibitor in a basket of cholestatic liver diseases, maralixibat showed a statistically significant placebo-adjusted pruritus reduction of -0.98 vs. placebo (p = 0.0004) on the 0-4 scale of the ItchRO(Obs) primary endpoint (longitudinal data in Exhibit 1). Roughly speaking, this means that the patients on this study, all of which had confirmed clinically meaningful pruritus (cutoff for ItchRo(Obs) > 1.5), experienced a mean pruritus reduction of -1.8 after starting

Mirum gains as Phase 3 LIVMARLI trial meets primary endpoint in liver disease

Mon, 12 Oct 2026 09:42:05 -0400

Investing.com -- Mirum Pharmaceuticals Inc (NASDAQ:MIRM) shares advanced 2.9% in premarket trading after the rare disease specialist announced positive topline results from its Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) in patients with ultra-rare cholestatic liver diseases.

The study achieved its primary endpoint by demonstrating a statistically significant reduction in cholestatic pruritus compared with placebo in pediatric patients, while also meeting all five prespecified secondary endpoints.

Patients receiving maralixibat experienced a mean 1.81-point improvement from baseline in their worst-daily itch severity score compared to a 0.83-point improvement for placebo, representing a placebo-adjusted treatment difference of 0.98

TD Cowen on Mirum Pharmaceuticals (MIRM): 'We continue to view shares as undervalued'

Mon, 12 Oct 2026 09:36:26 -0400

TD Cowen analyst Joseph Thome reiterated a Buy rating and $140.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).

The analyst comments "Today's news follows the approval of Atebrioz (zilurgisertib) in FOP (note here) and positive Phase III AZURE-1 data of brelovitug in HDV (note here). Data from the second pivotal study of brelovitug in HDV are expected this quarter. MIRM has the potential to add up to four additional opportunities in the next 1-2 years (PSC, PBC, HDV, and ultra-rare cholestatic diseases). MIRM estimates these could add a further $2B+ in peak sales on top of an already solid commercial base.

RBC Capital on Mirum (MIRM): 'we could see MIRM shares up 5–10% on the EXPAND news'

Mon, 12 Oct 2026 09:35:04 -0400

RBC Capital analyst Lisa Walter reiterated an Outperform rating and $155.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).

The analyst comments "We note this is the 4th pivotal study (in addition to PSC, HepD, FOP) this year that has read out positively for MIRM and we like the impressive track record. We view the data positively and given the primary endpoint was hit with high statistical significance in indications with no approved therapies we think FDA likely to approve MRX for a label expansion. EXPAND delivered a clean primary endpoint win with rapid (as early as week 1) and sustained pruritus

RBC Capital on Mirum (MIRM): 'we could see MIRM shares up 5–10% on the EXPAND news'

Mon, 12 Oct 2026 09:35:04 -0400

RBC Capital analyst Lisa Walter reiterated an Outperform rating and $155.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).

Baird on Mirum Pharmaceuticals (MIRM): 'we expect upside for the stock'

Mon, 12 Oct 2026 09:34:35 -0400

Baird analyst Brian Skorney reiterated an Outperform rating and $130.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).

The analyst comments "Incrementally positive on EXPAND success. Mirum announced the Ph3 EXPAND basket study of maralixibat in additional cholestatic indications, about half biliary atresia patients, met the primary and all secondary endpoints, with impressive reductions in pruritus and serum bile acids that we see as highly likely to support a label expansion. The safety/tolerability profile was in line with the Livmari label. Management didn't provide a change in the guidance for peak annual sales of $1B+, but a likely approval substantially expands the

Baird on Mirum Pharmaceuticals (MIRM): 'we expect upside for the stock'

Mon, 12 Oct 2026 09:34:35 -0400

Baird analyst Brian Skorney reiterated an Outperform rating and $130.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).

Stifel on Mirum Pharmaceuticals (MIRM): 'We think the opportunity here remains under-appreciate'

Mon, 12 Oct 2026 09:30:55 -0400

Stifel analyst James Condulis reiterated a Buy rating and $136.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).

The analyst comments "Next steps: MIRM plans to file an sNDA 1H27. We think the opportunity here remains under-appreciated with an overall addressable population probably larger than ALGS and no competition (pricing also a tailwind). Naturally it's far too early to discuss what a label/ indication statement may look like but, like with PFIC/ALGS, management expects it to be relatively broad (e.g., no upper age limit). Meanwhile, MIRM now more explicitly points to "addressable" patients (native liver + cholestatic pruritus), where they note the

Mirum's maralixibat meets primary endpoint in rare liver disease trial

Mon, 12 Oct 2026 08:00:45 -0400

Mirum Pharmaceuticals (Nasdaq: MIRM) announced that its Phase 3 EXPAND study of maralixibat (Livmarli) met its primary endpoint in patients with ultra-rare cholestatic liver diseases, including biliary atresia, according to a company press release.

The study enrolled 52 patients — 46 pediatric and six adults — who were randomized during a 20-week double-blind period to receive maralixibat 285 µg/kg twice daily or placebo. Maralixibat demonstrated a statistically significant reduction in cholestatic pruritus compared with placebo (p=0.0004), with a mean 1.81-point improvement from baseline in the ItchRO(Obs) severity score versus 0.83 points for placebo. The drug also produced a 70.1% reduction from

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

Mon, 12 Oct 2026 08:00:00 -0400

- Maralixibat demonstrated a statistically significant reduction in cholestatic pruritus compared with placebo (p=0.0004), and a 69% reduction in serum bile acids versus placebo (p<0.0001)

- In patients with biliary atresia, maralixibat demonstrated a statistically significant reduction in cholestatic pruritus compared with placebo (p=0.0002)

- Mirum plans U.S. sNDA submission in the first half of 2027 based on positive EXPAND results

- Mirum to host conference call to discuss topline results today, October 12, at 8:30 a.m. ET

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced topline results from

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

Mon, 12 Oct 2026 08:00:00 -0400

- Maralixibat demonstrated a statistically significant reduction in cholestatic pruritus compared with placebo (p=0.0004), and a 69% reduction in serum bile acids versus placebo (p<0.0001)

- In patients with biliary atresia, maralixibat demonstrated a statistically significant reduction in cholestatic pruritus compared with placebo (p=0.0002)

- Mirum plans U.S. sNDA submission in the first half of 2027 based on positive EXPAND results

- Mirum to host conference call to discuss topline results today, October 12, at 8:30 a.m. ET

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced topline results from

Mirum Pharmaceuticals to release Phase 3 maralixibat study results

Sun, 11 Oct 2026 17:00:09 -0400

Mirum Pharmaceuticals (NASDAQ: MIRM) announced it will host an investor call on October 12, 2026, at 8:30 a.m. ET to share topline results from its Phase 3 EXPAND study of LIVMARLI (maralixibat).

The study evaluates maralixibat for the treatment of cholestatic pruritus in patients aged six months or older with ultra-rare cholestatic liver diseases, including biliary atresia.